Recently, a study demonstrated that MARCH1 was overexpressed in ovarian cancer tissues, silencing MARCH1 inhibits the proliferation, migration and invasion of the ovarian cancer cells by down‐regulating the NF‐κB and Wnt/β‐catenin pathways.13 These data suggest that MARCH1 may be a proto‐oncogene that promotes tumour progression and, hence, a potential molecular target for cancer therapy. The gene discussed is NFKB1; the disease is ovarian cancer.